Tamiflu slumps but oncology strong for Chugai
This article was originally published in Scrip
Overall revenues at Roche's Japanese subsidiary, Chugai, slipped by 8% to ¥87.1 billion ($924.6 million) in the first quarter to 31 March, hit by a sharp drop in sales of Tamiflu (oseltamivir).
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.